ArticleJournal of gynecologic oncology2026
Association of immunohistochemically defined molecular subtypes with substantial lymphovascular space invasion in early-stage endometrial cancer: a single-center cohort of 575 patients.
Article in Journal of gynecologic oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the association between immunohistochemically (IHC) defined molecular subtypes and substantial lymphovascular space invasion (LVSI) in early-stage endometrial cancer (EC) according to the International Federation of Gynecology and Obstetrics (FIGO) 2023 classification.
methodsThis study included 575 patients who underwent primary surgery for FIGO stage I-II EC between January 2023 and April 2025. LVSI was assessed using World Health Organization criteria and classified as no/focal (Group 1, n=520) or substantial (Group 2, n=55). Molecular subtypes were determined using a surrogate IHC-based approach (no specific molecular profile, mismatch repair-deficient [MMRd], p53-abnormal [p53abn]); POLE mutation analysis was performed in a subset of patients. Clinicopathological variables were compared between groups, and independent predictors of substantial LVSI were identified using multivariable logistic regression.
resultsSubstantial LVSI was observed in 9.6% of patients (n=55). MMRd (18.5% vs. 34.5%) and p53abn (11% vs. 20%) subtypes were more frequent in the substantial LVSI group (p=0.001). Deep myometrial invasion (≥50%) (21.9% vs. 70.9%, p<0.001), cervical stromal invasion (4.8% vs. 16.4%, p=0.003), and adjuvant therapy (34.6% vs. 92.7%, p<0.001) were also associated with substantial LVSI. Multivariable analysis identified MMRd subtype (adjusted odds ratio [aOR]=2.916; 95% confidence interval [CI]=1.466-5.801; p=0.002) and ≥50% myometrial invasion (aOR=7.935; 95% CI=4.173-15.091; p<0.001) as independent predictors.
conclusionIn early-stage EC, substantial LVSI is associated with the MMRd molecular subtype and deep myometrial invasion. Understanding the molecular tumor biology underlying LVSI may facilitate more individualized risk stratification and treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.